Skip to main content
Journals

Socially Transformative Aesthetics: Real-World Evidence of Positive First Impressions After Pan-Facial Aesthetic Treatments

Aesthetic Surgery Journal Open Forum
Aesthetic Surgery Journal Open Forum

Authors: Steven Dayan, MD , Julia K Garcia, PhD, MS , Nazanin Ashourian, PhD , Sara Sangha, PhD , Vaishali Patel, PharmD, MS

Abstract: Minimally invasive, pan-facial aesthetic treatments rejuvenate and improve facial appearance and may impact social interactions and perceptions. This observational pilot study used video recordings and in-person evaluations to assess social perceptions of participants before and after pan-facial treatment. Adults receiving pan-facial injectable treatments (ie, onabotulinumtoxinA [Botox Cosmetic, Allergan Aesthetics, Westport, Ireland], hyaluronic acid fillers [Juvéderm; Allergan Aesthetics, Irvine, California], or both) were invited to participate. Three measures were developed to assess perceptions of attractiveness, approachability, naturalness, trustworthiness, healthiness, and age from nonclinical observer, patient participant, and clinician perspectives: the Pan-Facial Treatment Outcome Survey, the Participant Perception of Appearance, and the Clinician Perception of Appearance. Twenty-seven participants received treatment and provided video recordings, with 16 videos (n = 8 participants) selected for the study; 298 individuals enrolled as nonclinical observers. Compared with baseline assessments, nonclinical observer–reported posttreatment scores were significantly higher for perceptions of attractiveness, approachability, naturalness, healthiness, and perceived age (all P values < .05). Posttreatment participant- and clinician-reported scores were significantly higher for the same domains as well as trustworthiness (all P values < .05). Compared with baseline, participants and the clinician perceived participants as younger compared to their actual age (3.6 years younger and 2.5 years younger, respectively), and nonclinical observers perceived participants as within 6 months of their actual age after pan-facial treatment. Pan-facial treatments may positively impact social perceptions and self-assessments of facial appearance. These benefits extend beyond physical appearance, including improving overall social interactions and personal well-being.

JOURNAL ARTICLE

Related Articles

Poly-L-lactic acid (PLLA) is a biostimulatory injectable that restores midfacial volume through collagen neogenesis rather than gel-based filling. Controlled clinical evidence directly quantifying PLLA's volumetric efficacy remains limited. This study aimed to evaluate the efficacy, safety, and patient-reported outcomes of a Norberg Medical PLLA formulation for midface rejuvenation in a prospective, evaluator-blinded, split-face controlled study.
Conventional botulinum toxin type A (BoNT/A) products include non-therapeutic accessory proteins vary in composition and manufacturing processes, which may contribute to differences in purity and biochemical characteristics. YY001 (Retoxin®) is a novel recombinant BoNT/A manufactured via E. coli expression to reduce impurities, improve purity, and minimize immunogenic risk.
Botulinum neurotoxin A (BoNT-A) is widely used clinically; yet, its temporary effects require repeated injections that increase cost and inconvenience. There is limited rigorous evidence to support claims that repeated BoNT-A use alters efficacy. Unlike peripheral nerve transection, which causes irreversible denervation after 12 to 24 months, the long-term physiological effects of BoNT-A chemodenervation remain unclear.